CJ has been granted a patent for a fructose-4-epimerase variant with tagatose conversion activity. The method involves substituting specific amino acids in the sequence to achieve at least 90% identity to the original sequence. GlobalData’s report on CJ gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on CJ, NSAID cancer drugs was a key innovation area identified from patents. CJ's grant share as of January 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for fructose-4-epimerase variant for tagatose conversion
See Also:
A recently granted patent (Publication Number: US11884923B2) discloses a fructose-4-epimerase variant with specific amino acid substitutions, aimed at enhancing its efficiency in producing tagatose. The variant, with substitutions at key positions such as 52, 136, 197, 317, 320, and 414 from the N-terminus, must have at least 90% sequence identity to the original amino acid sequence (SEQ ID NO: 1) to be considered within the scope of the patent.
The patent also covers compositions and methods for producing tagatose using the aforementioned fructose-4-epimerase variant. The compositions include the variant along with fructose, while the methods involve converting fructose into tagatose by utilizing the variant. By specifying the amino acid substitutions and their positions, the patent aims to provide a more efficient and effective way of producing tagatose, a valuable sweetener with various applications in the food industry.
To know more about GlobalData’s detailed insights on CJ, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.